324 related articles for article (PubMed ID: 29606379)
21. Aflibercept Monotherapy versus Bevacizumab-First for Diabetic Macular Edema: A Cost Analysis Based on Diabetic Retinopathy Clinical Research Network Protocol AC Results.
Patel NA; Al-Khersan H; Yannuzzi NA; Lin J; Smiddy WE
Ophthalmol Retina; 2023 May; 7(5):413-419. PubMed ID: 36423893
[TBL] [Abstract][Full Text] [Related]
22. Sequence effect in the treatment of proliferative diabetic retinopathy with intravitreal ranibizumab and panretinal photocoagulation.
Cao G; Xu X; Wang C; Zhang S
Eur J Ophthalmol; 2020 Jan; 30(1):34-39. PubMed ID: 30539668
[TBL] [Abstract][Full Text] [Related]
23. Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy.
Messias A; Ramos Filho JA; Messias K; Almeida FP; Costa RA; Scott IU; Gekeler F; Jorge R
Doc Ophthalmol; 2012 Jun; 124(3):225-36. PubMed ID: 22457045
[TBL] [Abstract][Full Text] [Related]
24. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial.
Bressler SB; Qin H; Melia M; Bressler NM; Beck RW; Chan CK; Grover S; Miller DG;
JAMA Ophthalmol; 2013 Aug; 131(8):1033-40. PubMed ID: 23807371
[TBL] [Abstract][Full Text] [Related]
25. Intravitreal ranibizumab versus vitrectomy for recurrent vitreous haemorrhage after pars plana vitrectomy for proliferative diabetic retinopathy: a prospective study.
Chatziralli I; Dimitriou E; Theodossiadis G; Bourouki E; Bagli E; Kitsos G; Theodossiadis P
Int Ophthalmol; 2020 Apr; 40(4):841-847. PubMed ID: 31788713
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
Ross EL; Hutton DW; Stein JD; Bressler NM; Jampol LM; Glassman AR;
JAMA Ophthalmol; 2016 Aug; 134(8):888-96. PubMed ID: 27280850
[TBL] [Abstract][Full Text] [Related]
27. Panretinal Photocoagulation for Diabetic Retinopathy in the RIDE and RISE Trials: Not "1 and Done".
Gonzalez VH; Wang PW; Ruiz CQ
Ophthalmology; 2021 Oct; 128(10):1448-1457. PubMed ID: 31668888
[TBL] [Abstract][Full Text] [Related]
28. Effect of intravitreal ranibizumab pretreatment on vitrectomy in young patients with proliferative diabetic retinopathy.
Chen HJ; Wang CG; Dou HL; Feng XF; Xu YM; Ma ZZ
Ann Palliat Med; 2020 Jan; 9(1):82-89. PubMed ID: 32005066
[TBL] [Abstract][Full Text] [Related]
29. Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy after Panretinal Photocoagulation or Intravitreal Anti-VEGF Injections.
Obeid A; Gao X; Ali FS; Talcott KE; Aderman CM; Hyman L; Ho AC; Hsu J
Ophthalmology; 2018 Sep; 125(9):1386-1392. PubMed ID: 29606377
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal anti-vascular endothelial growth factors, panretinal photocoagulation and combined treatment for proliferative diabetic retinopathy: a systematic review and network meta-analysis.
Fallico M; Maugeri A; Lotery A; Longo A; Bonfiglio V; Russo A; Avitabile T; Pulvirenti A; Furino C; Cennamo G; Barchitta M; Agodi A; Reibaldi M
Acta Ophthalmol; 2021 Sep; 99(6):e795-e805. PubMed ID: 33326183
[TBL] [Abstract][Full Text] [Related]
31. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.
Brown GC; Brown MM; Turpcu A; Rajput Y
Ophthalmology; 2015 Jul; 122(7):1416-25. PubMed ID: 25935787
[TBL] [Abstract][Full Text] [Related]
32. Proliferative diabetic retinopathy treated with intravitreal ranibizumab and photocoagulation directed at ischemic retinal areas-A randomized study.
Toscano L; Messias A; Messias K; de Cenço Lopes R; Ribeiro JAS; Scott IU; Jorge R
Doc Ophthalmol; 2021 Dec; 143(3):313-322. PubMed ID: 34347216
[TBL] [Abstract][Full Text] [Related]
33. The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema.
Lang GE; Liakopoulos S; Vögeler J; Weiß C; Spital G; Gamulescu MA; Lohmann C; Wiedemann P
Acta Ophthalmol; 2018 May; 96(3):e377-e385. PubMed ID: 29090846
[TBL] [Abstract][Full Text] [Related]
34. Cost-Utility Analysis of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
Brown GC; Brown MM; Monigle MC
Ophthalmol Retina; 2024 May; 8(5):431-446. PubMed ID: 37981235
[TBL] [Abstract][Full Text] [Related]
35. The impact of ranibizumab on the level of intercellular adhesion molecule type 1 in the vitreous of eyes with proliferative diabetic retinopathy.
Yan Y; Zhu L; Hong L; Deng J; Song Y; Chen X
Acta Ophthalmol; 2016 Jun; 94(4):358-64. PubMed ID: 26285163
[TBL] [Abstract][Full Text] [Related]
36. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.
Diabetic Retinopathy Clinical Research Network*
JAMA Ophthalmol; 2013 Mar; 131(3):283-93. PubMed ID: 23370902
[TBL] [Abstract][Full Text] [Related]
37. The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage.
Li S; Yang Y; Zou J; Zeng J; Ding C
BMC Ophthalmol; 2022 Feb; 22(1):63. PubMed ID: 35139812
[TBL] [Abstract][Full Text] [Related]
38. Effects of intravitreal injection of ranibizumab on choroidal structure and blood flow in eyes with diabetic macular edema.
Okamoto M; Yamashita M; Ogata N
Graefes Arch Clin Exp Ophthalmol; 2018 May; 256(5):885-892. PubMed ID: 29492689
[TBL] [Abstract][Full Text] [Related]
39. Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy.
Sun JK; Glassman AR; Beaulieu WT; Stockdale CR; Bressler NM; Flaxel C; Gross JG; Shami M; Jampol LM;
Ophthalmology; 2019 Jan; 126(1):87-95. PubMed ID: 30096354
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.
Obeid A; Su D; Patel SN; Uhr JH; Borkar D; Gao X; Fineman MS; Regillo CD; Maguire JI; Garg SJ; Hsu J
Ophthalmology; 2019 Mar; 126(3):407-413. PubMed ID: 30077614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
